Filtered By:
Drug: Taxotere
Procedure: Prostatectomy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 13 results found since Jan 2013.
New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & amp; therapeutics
Front Oncol. 2023 Aug 17;13:1193736. doi: 10.3389/fonc.2023.1193736. eCollection 2023.ABSTRACTProstate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate th...
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Neha Thakur Sameer Quazi Bindu Naik Saurabh Kumar Jha Pallavi Singh Source Type: research
Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers
This study utilized bulk and single-cell or whole-transcriptome analysis [(RNA sequencing (RNA-seq) and single-cell RNA sequencing (scRNA-seq)], and we observed greater expression of several EMT markers, including Vimentin, hyaluronan synthase-3, S100 calcium binding protein A6, TGFB1, CD44, CD55, and CD109 in European American and African American aggressive variant prostate cancer (AVPC) subtypes-mCRPC, neuroendocrine variant (NEPC), and taxane-resistant. The taxane-resistant gene FSCN1 was also expressed highly in single-cell subclonal populations in mCRPC. Furthermore, metronomic-topotecan single agent and combinations...
Source: Cell Research - July 21, 2023 Category: Cytology Authors: Taraswi Mitra Ghosh Suman Mazumder Joshua Davis Jyoti Yadav Ayuba Akinpelu Ahmed Alnaim Harish Kumar Razan Waliagha Allison E Church Bird Soroush Rais-Bahrami R Curtis Bird Panagiotis Mistriotis Amarjit Mishra Clayton C Yates Amit K Mitra Robert D Arnold Source Type: research
Novel Approaches in the Systemic Management of High-Risk Prostate Cancer
Clin Genitourin Cancer. 2023 Jun 18:S1558-7673(23)00140-4. doi: 10.1016/j.clgc.2023.06.001. Online ahead of print.ABSTRACTLocally advanced prostate cancer comprises approximately 20% of new prostate cancer diagnoses. For these patients, international guidelines recommend treatment with radiotherapy (RT) to the prostate in combination with long-term (2-3 years) androgen deprivation therapy (ADT), or radical prostatectomy in combination with extended pelvic lymph node dissection (PLND) as another treatment option for selected patients as part of multimodal therapy. Improvements in overall survival with docetaxel or an androg...
Source: Clinical Prostate Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Maria Antonia G ómez-Aparicio Fernando L ópez-Campos Antonio Jos é Lozano Xavier Maldonado Bego ña Caballero Juan Zafra Vladamir Suarez Elena Moreno Stefano Arcangeli Marta Scorsetti Felipe Cou ñago Source Type: research
What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
ConclusionThe present review discusses current data in de novo, omPCa regarding its definition, the increasing role of molecular imaging, the place of local and metastasis-directed therapies, and the intensification of systemic therapies.
Source: World Journal of Urology - December 9, 2022 Category: Urology & Nephrology Source Type: research
The current role of local treatment in metastatic prostate cancer: systematic review and meta-analysis
CONCLUSION: Recent data have shown that local treatment combined with systematic therapy, might improve the overall, cancer-specific, and failure-free survivals of patients diagnosed with metastatic prostate cancer. Furthermore, local treatment is both feasible and safe. Further studies evaluating the quality of life of these patients are needed.PMID:36258673 | DOI:10.1080/0284186X.2022.2132113
Source: Acta Oncologica - October 19, 2022 Category: Cancer & Oncology Authors: Willy Baccaglini Antonio F Rodrigues Saulo B Teles Nicolle M Christofe Felipe P A Glina Gustavo C Lemos Rafael Sanchez-Salas Rub én Olivares Arie Carneiro Source Type: research
Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs
CONCLUSIONS: Cooperation of PSMA-specific CAR-T cells and the chemotherapy drug docetaxel can impressively ameliorate antitumor effectiveness against an installed metastatic human prostate cancer model in NPG mice.PMID:35962287 | DOI:10.1007/s00432-022-04248-y
Source: Cell Research - August 12, 2022 Category: Cytology Authors: Xiaokang Zhang Shishuo Sun Yangna Miao Yifan Yuan Wanxin Zhao Hailong Li Xiaohuan Wei Chao Huang Xiaolei Hu Bixi Wang Heng Xu Wei Zhang Xiaoge Gao Jingyuan Song Junnian Zheng Qing Zhang Source Type: research
The cytoreductive radical prostatectomy in metastatic prostate cancer
This article aims to provide an overview of key published or ongoing studies related to CP in relation not only to functional and oncological results but also to the indication criteria and design of individual studies.PMID:35236082 | DOI:10.48095/ccko202255
Source: Cancer Control - March 3, 2022 Category: Cancer & Oncology Authors: Študent Vladimír Seifriedov á Zuzana Študentová Hana Source Type: research
Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis
CONCLUSIONS: PSM analysis revealed NCHT before RP in OMPC patients has potential therapeutic benefits with acceptable toxicities and lower incidence of postoperative positive surgical margins.PMID:33824096 | DOI:10.1016/j.clgc.2021.02.004
Source: Clinical Prostate Cancer - April 7, 2021 Category: Cancer & Oncology Authors: Chenfei Chi Liancheng Fan Baijun Dong Yinjie Zhu Zhixiang Xin Jiahua Pan Wei Xue Source Type: research
French ccAFU guidelines - update 2020-2022: prostate cancer.
CONCLUSION: - These updated french guidelines will contribute to increase the level of urological care for the diagnosis and treatment for prostate cancer.
PMID: 33349424 [PubMed - in process]
Source: Progres en Urologie - December 24, 2020 Category: Urology & Nephrology Tags: Prog Urol Source Type: research
